


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on March 9, 2007.

  
\_\_\_\_\_  
Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 CFR  
§1.825(a) THROUGH (c)  
Patent Application  
Docket No. ARS-124  
Serial No. 10/573,625

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson  
Serial No. : 10/573,625  
Filed : March 28, 2006  
Conf. No. : 9024  
For : Therapeutic Uses of Chemokine Variants

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: